3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
25
Thoracic
22
Genitourinary
14
Gynecologic
10
Head & Neck
7
Dermatologic
6
Breast
6
Lymphoid
1
Conditions
Lymphoma, Follicular
200
Lymphoma
199
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Leukemia
89
Hodgkin Disease
89
Lymphoma, Mantle-Cell
80
Lymphoma, B-Cell, Marginal Zone
66
Burkitt Lymphoma
65
Leukemia, Myeloid, Acute
55
Multiple Myeloma
52
Lymphoma, Large-Cell, Immunoblastic
48
Recurrence
44
Neoplasms
38
Myelodysplastic Syndromes
38
Lymphoma, T-Cell, Cutaneous
36
Mycosis Fungoides
30
Lymphoma, Large-Cell, Anaplastic
30
Waldenstrom Macroglobulinemia
28
Leukemia, Myeloid, Chronic-Phase
28
Myeloproliferative Disorders
27
Lymphoma, B-Cell
27
Leukemia, Myeloid, Accelerated Phase
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
26
Sezary Syndrome
25
Leukemia, Biphenotypic, Acute
25
Blast Crisis
24
Primary Myelofibrosis
22
Interventions
pembrolizumab
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Lymphoid
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA